The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma

Trial Profile

The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary) ; Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms BeST
  • Most Recent Events

    • 14 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 17 Jun 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 16 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top